269 related articles for article (PubMed ID: 17885490)
21. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Ali-Fehmi R; Morris RT; Bandyopadhyay S; Che M; Schimp V; Malone JM; Munkarah AR
Am J Obstet Gynecol; 2005 Mar; 192(3):819-25. PubMed ID: 15746677
[TBL] [Abstract][Full Text] [Related]
22. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
Geisler JP; Wiemann MC; Miller GA; Geisler HE
Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651
[TBL] [Abstract][Full Text] [Related]
23. Quantification of ER/PR expression in ovarian low-grade serous carcinoma.
Escobar J; Klimowicz AC; Dean M; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Köbel M
Gynecol Oncol; 2013 Feb; 128(2):371-6. PubMed ID: 23103384
[TBL] [Abstract][Full Text] [Related]
24. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
25. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
26. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths.
Alshenawy HA
Ann Diagn Pathol; 2010 Dec; 14(6):387-95. PubMed ID: 21074685
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery.
Zhu Y; Zhou XY; Yao XD; Dai B; Ye DW
BJU Int; 2007 Jul; 100(1):204-8. PubMed ID: 17433031
[TBL] [Abstract][Full Text] [Related]
32. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
Solomon LA; Munkarah AR; Schimp VL; Arabi MH; Morris RT; Nassar H; Ali-Fehmi R
Gynecol Oncol; 2006 Jun; 101(3):385-9. PubMed ID: 16443262
[TBL] [Abstract][Full Text] [Related]
33. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
Ordóñez NG
Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
[TBL] [Abstract][Full Text] [Related]
34. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
35. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
36. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
Lee P; Rosen DG; Zhu C; Silva EG; Liu J
Gynecol Oncol; 2005 Mar; 96(3):671-7. PubMed ID: 15721410
[TBL] [Abstract][Full Text] [Related]
37. [Expression of heat shock protein-70, estrogen receptor and progesterone receptor in ovarian carcinomas and the correlation between HSP70 and sex steroid receptor].
Xing Y; Tang Z; Liao Y; Zhu SF; Li ZM; Chen ML
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jul; 35(4):486-8. PubMed ID: 15291106
[TBL] [Abstract][Full Text] [Related]
38. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
[TBL] [Abstract][Full Text] [Related]
39. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
40. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
